Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTB-Tim3 scFv-expressing Lactococcus lactis
- Development stage
- Preclinical
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intranasal, Intragastric, Intravaginal, Intraperitoneal
01
Overview
CTB-Tim3 scFv-expressing Lactococcus lactis is an experimental live biotherapeutic product consisting of the food-grade bacterium *Lactococcus lactis* genetically engineered to express and secrete a fusion protein. This protein comprises a single-chain variable fragment (scFv) targeting T-cell immunoglobulin-3 (Tim-3) fused to the cholera toxin B subunit (CTB), which acts as a mucosal adjuvant and carrier. Tim-3 is an inhibitory immune checkpoint molecule that, when blocked, can revitalize exhausted T-cells and enhance anti-tumor immunity. Developed as a cost-effective alternative to traditional monoclonal antibodies, this microbial delivery system has demonstrated the ability to promote lymphocyte activation and inhibit tumor growth, proliferation, and angiogenesis in preclinical models of renal cell carcinoma.
- Other names
- Tim3scFv-Transforming LactobacillusTim-3scFv-Transforming LactobacillusTim 3scFv-Transforming LactobacillusTim3scFv-Transforming Lactococcus lactisTim-3scFv-Transforming Lactococcus lactisTim 3scFv-Transforming Lactococcus lactisNZ-CTB-Tim3scFvNZ-CTB-Tim-3scFvNZ-CTB-Tim 3scFv
02
Targets
HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on CTB-Tim3 scFv-expressing Lactococcus lactis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTB-Tim3 scFv-expressing Lactococcus lactis.